ABSI
Absci Corporation
Company Overview
| Mkt Cap | $533.80M | Price | $3.73 |
| Volume | 3.73M | Change | -2.99% |
| P/E Ratio | -5.2 | Open | $3.83 |
| Revenue | $4.5M | Prev Close | $3.84 |
| Net Income | $-103.1M | 52W Range | $2.01 - $6.33 |
| Div Yield | N/A | Target | $8.11 |
| Overall | 65 | Value | 60 |
| Quality | 44 | Technical | 91 |
No chart data available
About Absci Corporation
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest News
These 3 Under-the-Radar Stocks Have Triple-Digit Upside Potential – 12/5/2025
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbSci (ABSI) and Praxis Precision Medicines (PRAX)
Absci Reports Q3 Results, Focuses on ABS-201
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABSI | $3.73 | -3.0% | 3.73M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |